MVA-EL

N/A

Report date: 2025/08/27 20:01:50

Base Information

Drug NameMVA-EL
Drug Alias NameMVA-EBNA1/LMP2
ClassificationVaccines > Application > Therapeutic vaccineVaccines > Development/production technology > Recombinant vector vaccine
Mechanisms of ActionT-cell surface antigen CD4 inhibitorsImmunostimulants
TargetsT-cell surface antigen CD4
Therapy Area/IndicationsLymphoproliferative DisordersNasopharyngeal NeoplasmsHead and Neck Neoplasms +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited KingdomHong Kong
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesChinese University Of Hong Kong (Cuhk)Cancer Research UK
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesChinese University Of Hong Kong (Cuhk)Cancer Research UK
Active IndicationsN/A
Inactive IndicationsLymphoproliferative DisordersNasopharyngeal NeoplasmsHead and Neck Neoplasms +[6] 

Other Information

ATC CodeN/A
Related LinksN/A